Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2015

01-04-2015 | Review Article

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Authors: Alois Gratwohl, Helen Baldomero, Jakob Passweg

Published in: Annals of Hematology | Special Issue 2/2015

Login to get access

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently recommended as 2nd or 3rd line therapy for patients with chronic myeloid leukemia (CML) in first chronic phase or as salvage for patients with very advanced disease. As a consequence, numbers of HSCT in chronic phase have dropped significantly since the introduction of tyrosine kinase inhibitors (TKI), numbers of transplants in advanced disease to a lesser extent. These current recommendations consider primarily disease risk, defined as failure of TKI therapy; they might need to be adapted. We propose a more balanced appraisal of HSCT for individual patients which should include disease risk, transplant risk, and macroeconomic aspects. HSCT should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk. For patients with very advanced disease and high transplant risk in contrast, HSCT might only be recommended in a restricted research setting.
Literature
1.
Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357(3):258–265CrossRefPubMed
2.
3.
4.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, Investigators IRIS (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004CrossRefPubMed
5.
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, IRIS investigators (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758–3765. doi:10.​1182/​blood-2010-03-273979 CrossRefPubMedCentralPubMed
6.
7.
Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G (2014) First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 74(6):627–643CrossRefPubMed
8.
9.
10.
Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1(8378):665–668CrossRefPubMed
11.
Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A (2013) European group for blood and marrow transplantation. Bone Marrow Transplant 48(9):1161–1167. doi:10.​1038/​bmt.​2013.​51 CrossRefPubMedCentralPubMed
12.
Mackinnon S, Goldman JM (1987) Bone marrow transplantation for CML. Baillieres Clin Haematol 1(4):1055–1076CrossRefPubMed
13.
Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M (2013) ESMO guidelines working group. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Onco 24(Suppl 6):vi133–vi137. doi:10.​1093/​annonc/​mdt297
14.
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A (2014) European myeloma network. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232–242. doi:10.​3324/​haematol.​2013.​099358 CrossRefPubMedCentralPubMed
15.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101. doi:10.​1056/​NEJMoa1004383 CrossRefPubMedCentralPubMed
16.
Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, Baldomero H, Chabannon C, Apperley J, Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, and the European Leukemia Net (2014) Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica 99(5):908–915CrossRefPubMedCentralPubMed
17.
Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, Neiman PE, Storb R (1974) Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 290(25):1389–1393CrossRefPubMed
18.
Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314(4):202–207CrossRefPubMed
19.
Gratwohl A, Schwendener A, Baldomero H et al (2010) Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica 95:637–643CrossRefPubMedCentralPubMed
20.
Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352(9134):1087–1092CrossRefPubMed
21.
Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20):4715–4726. doi:10.​1002/​cncr.​24531 CrossRefPubMed
22.
23.
Gratwohl A, Goldman J, Gluckman E, Zwaan F (1985) Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia. Lancet 2(8467):1290–1291CrossRefPubMed
24.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304(25):1529–1533CrossRefPubMed
25.
Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12):2462–2465PubMed
26.
Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from. HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolatemofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629CrossRefPubMed
27.
28.
Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D, Worldwide Network of Blood and Marrow Transplantation (WBMT) (2013) Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 98(8):1282–1290. doi:10.​3324/​haematol.​2012.​076349 CrossRefPubMedCentralPubMed
29.
Pasquini MC (2012) Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 17(Suppl 1):S79–S82PubMed
30.
López-Hernández MA, Alvarado-Ibarra M, González-Avante CM (2011) Overall survival of chronic myeloid leukemia patients treated with related donor hematopoieticstemcell transplant or imatinib. Rev Invest Clin 63(5):494–499PubMed
31.
Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335(8700):1255–1258CrossRefPubMed
32.
Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A (1994) Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European group for bone marrow transplantation. Chronic leukemia working party of the EBMT. Bone Marrow Transplant 14(3):407–410PubMed
33.
Autograft Trials Collaboration CML (2007) Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials. Cancer Treat Rev 33(1):39–47CrossRef
34.
35.
Sorror ML (2010) Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hemato lEduc Program 2010:237–247CrossRef
36.
Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Vina M, Petersdorf E, Bray R, Hartzman RJ, Ng J, Hurley CK (2008) Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplan 14:37–44CrossRef
37.
Latham K, Little AM, Madrigal JA (2014) An overview of HLA typing for hematopoietic stem cell transplantation. Methods Mol Biol 1109:73–85CrossRefPubMed
38.
Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE (2014) Unrelated adult stem cell donor medical suitability: recommendations from the world marrow donor association clinical working group committee. Bone Marrow Transplant. doi:10.​1038/​bmt.​2014.​67
39.
Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic. HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316–1324CrossRefPubMedCentralPubMed
40.
Bar M, Radich J (2013) Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia. J Natl Compr Canc Netw 11(3):308–315PubMed
41.
Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N (2013) Outcome of allogeneic. SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 92(4):487–496CrossRefPubMed
42.
Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D (2012) Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 119(17):4083–4090CrossRefPubMedCentralPubMed
43.
Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim D, Uhm J, Lambie A, Ellis L, Lipton JH (2014) A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 14:87–92CrossRefPubMed
44.
Lee SJ, Kukreja M, Wang T, Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500–3507CrossRefPubMedCentralPubMed
45.
Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885. doi:10.​1182/​blood-2009-08-237115 CrossRefPubMed
46.
Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M (2014) Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 4, CD010189. doi:10.​1002/​14651858.​CD010189.​pub2 PubMed
47.
48.
Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ (2012) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 47(6):810–816CrossRefPubMedCentralPubMed
49.
Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84(12):4064–4077PubMed
50.
Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11):4686–4692. doi:10.​1182/​blood-2006-11-055186 CrossRefPubMed
51.
Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; for the SchweizerischeArbeitsgemeinschaftfürKlinischeForschung (SAKK) and the German CML Study Group (2014) Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia J Cancer Res Clin Oncol Apr 10
52.
Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lai YY, Lv M, Huang XJ (2013) Imatinib results in better outcomes than. HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 27(12):2410–2413. doi:10.​1038/​leu.​2013.​159 CrossRefPubMed
53.
Liu YC, Hsiao HH, Chang CS, Liu TC, Yang WC, Hsu JF, Huang CT, Cho SF, Wu CH, Tsai YF, Lin SF (2013) Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited. Anticancer Res 33(10):4663–4667PubMed
54.
Hamidieh AA, Ansari S, Darbandi B, Soroush A, Arjmandi Rafsanjani K, Alimoghaddam K, Bahosh G, Behfar M, Ghavamzadeh A (2013) The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 17(4):380–386CrossRefPubMed
55.
Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL (2012) Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma 53(7):1321–1326CrossRefPubMed
56.
Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117(11):3032–3040CrossRefPubMed
57.
58.
59.
60.
Benyamini N, Rowe JM (2013) Is there a role for allogeneic transplantation in chronic myeloid leukemia? Expert Rev Hematol 6(6):759–765CrossRefPubMed
61.
Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981–1987CrossRefPubMedCentralPubMed
62.
Gratwohl A, Brand R, Niederwieser D et al (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29:1980–1986CrossRefPubMed
63.
64.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.​1182/​blood-2013-05-501569 CrossRefPubMed
65.
Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, Jiang H, Chen H, Chen YH, Zhang XH, Han W, Wang Y, Huang XJ (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49(4):576–580. doi:10.​1038/​bmt.​2013.​232 CrossRefPubMed
66.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R (2012) Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 16(42):1–277. doi:10.​3310/​hta16420 CrossRef
67.
68.
Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG (2012) Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics 28(6):823–830CrossRefPubMedCentralPubMed
69.
Cornelissen JJ, Gratwohl A, Schlenk RF et al (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9:579–590CrossRefPubMed
Metadata
Title
The role of hematopoietic stem cell transplantation in chronic myeloid leukemia
Authors
Alois Gratwohl
Helen Baldomero
Jakob Passweg
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue Special Issue 2/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2313-3

Other articles of this Special Issue 2/2015

Annals of Hematology 2/2015 Go to the issue

Review Article

The choice of first-line Chronic Myelogenous Leukemia treatment

Review Article

Discontinuation of tyrosine kinase therapy in CML

Review Article

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients

Review Article

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

Review Article

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death

Editorial

CML—where do we stand in 2015?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits